Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSD UCSF
Dates
study started
completion around
Principal Investigator
by Adam Burgoyne (ucsd)Huat Lim (ucsf)
Headshot of Adam Burgoyne
Adam Burgoyne

Description

Summary

The objective of the ROWAN clinical study is to assess the efficacy of local tumor control in HCC patients who receive TheraSphere followed by durvalumab and tremelimumab.

Official Title

An Open-Label, Prospective, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of TheraSphere™ Followed by Durvalumab (Imfinzi®) With Tremelimumab (Imjudo®) for Hepatocellular Carcinoma (HCC)

Details

A global open-label, prospective, multi-center Phase II trial designed to assess the safety and efficacy of TheraSphere administered before initiation of Durvalumab with Tremelimumab in HCC patients who are not a candidate for resection, thermal ablation or liver transplant at the time of study entry.

Keywords

Hepatocellular Carcinoma, Carcinoma, Carcinoma, Hepatocellular, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Neoplasms, Adenocarcinoma, Liver Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Digestive System Diseases, Liver Diseases, Durvalumab, Tremelimumab, Immunomodulating Agents, Immunologic Factors, TheraSphere Y-90 glass microsphere therapy, Durvalumab (Imfinzi) immunotherapy, Tremelimumab immunotherapy, TheraSphere followed by Durvalumab and Tremelimumab

Eligibility

Locations

  • University of California San Diego accepting new patients
    San Diego California 92093 United States
  • University of California San Francisco accepting new patients
    San Francisco California 94143 United States

Lead Scientists at University of California Health

  • Adam Burgoyne (ucsd)
    Associate Clinical Professor, Medicine, Vc-health Sciences-schools. Authored (or co-authored) 35 research publications
  • Huat Lim (ucsf)

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Boston Scientific Corporation
Links
Boston Scientific Website ROWAN Clinical Trial Overview
ID
NCT05063565
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 100 study participants
Last Updated